)
)
)
KaliVir Immunotherapeutics
March 02, 2026
Ballroom I C
Type: Company Presentation
Focus Area:
Oncology
KaliVir Immunotherapeutics is a clinical-stage biotechnology company at the forefront of developing next-generation oncolytic immunotherapies. By harnessing the unique advantages of the vaccinia platform, KaliVir engineers optimized viral backbones to create innovative candidates for cancer treatment. The Company's proprietary Vaccinia Enhanced Template (VET™) platform integrates multiple genetic modifications, allowing for the systemic delivery of oncolytic vaccinia candidates and the targeted expression of therapeutic transgenes within tumors. KaliVir is headquartered in Pittsburgh, Pennsylvania.
Year Founded:
2019
Lead Product in Development:
VET3-TGI is a novel oncolytic immunotherapy developed using KaliVir’s proprietary VET™ platform, designed to selectively replicate in tumor cells, stimulate local immune responses and remodel the immunosuppressive tumor microenvironment through the expression of IL-12 and a TGFβ inhibitor. By combining potent local immune activation with blockade of a key immunosuppressive pathway, the program is designed to drive durable, systemic anti-tumor responses across solid tumors.
Speakers
){kind=logo}
)
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
